Aplastic Anemia Market to Witness Significant Growth by 2034, Fueled by Rising Prevalence and a Strong Pipeline
The aplastic anemia treatment market is poised for significant growth, with key pharmaceutical companies including Novartis, Pfizer, Teva Pharmaceuticals, Kyowa Kirin, Regeneron Pharmaceuticals, Gamida Cell, and others leading therapeutic innovation in this rare hematologic disorder.
DelveInsight's " Aplastic Anemia Market Insight, Epidemiology And Market Forecast - 2034" report provides an in-depth understanding of aplastic anemia, including historical and forecasted epidemiology as well as market trends across the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.
According to the comprehensive analysis, the aplastic anemia market, valued at approximately USD 270 million in 2023 across the 7MM, is projected to expand substantially through 2034, fueled by increasing disease incidence, growing uptake of existing therapies, and the anticipated launch of promising pipeline candidates.
Furthermore, the US currently dominates the aplastic anemia treatment landscape, accounting for approximately 70% of the market share in the 7MM, followed by Japan with the second-highest market value at approximately USD 35 million in 2023. Among European nations, Germany leads the market, with additional growth anticipated across all regions during the forecast period.
Download the Aplastic Anemia Market Forecast Report to understand which factors are driving the Aplastic Anemia market @ Aplastic Anemia Market Trends.
DelveInsight's aplastic anemia epidemiological analysis reveals that Japan reported the highest aplastic anemia incident cases, contributing approximately 30% of cases across the 7MM in 2023. Notably, 56% of aplastic anemia cases were reported in individuals aged 60 and above, while 43% were below the age of 60.
Discover evolving trends in the Aplastic Anemia patient pool forecasts @ Aplastic Anemia Epidemiological Analysis.
The current aplastic anemia treatment varies based on patient age and disease severity. Hematopoietic stem cell transplantation (HSCT) remains the standard of care for patients under 40 years, while immunosuppressive therapy (IST) is preferred for those above 40 years. Novartis' PROMACTA / REVOLADE (eltrombopag) currently leads market revenue, followed by various immunosuppressive therapies. However, younger patients experience significantly better long-term survival compared to those aged 60 and above, highlighting a critical unmet need for improved management strategies in older populations.
The aplastic anemia therapeutic landscape is evolving with several marketed and emerging options. ALVAIZ (eltrombopag choline) from Teva Pharmaceuticals (NYSE: TEVA), an oral thrombopoietin receptor agonist that stimulates platelet production, approved in November 2023, represents an important treatment advancement. In Japan, Kyowa Kirin's ROMIPLATE has gained approval for patients showing inadequate response to conventional therapy.
The patent for PROMACTA (eltrombopag), a key treatment for aplastic anemia, is set to expire on July 13, 2025. This expiry will likely lead to the introduction of generic versions, which can reduce treatment costs and increase patient access. As Promacta is currently a leading therapy in the aplastic anemia market, the availability of generics is expected to intensify competition, lower prices, and potentially shift prescribing patterns.
Looking toward future market growth, promising pipeline candidates include REGN7257 from Regeneron Pharmaceuticals (NASDAQ: REGN), a gamma chain cytokine receptor antibody targeting the common gamma chain found in various interleukin receptors. Currently in Phase I/II clinical trials, this therapy aims to address T-cell-mediated pathogenesis in severe aplastic anemia patients who have relapsed after immunosuppressive therapy. Another noteworthy emerging therapy is OMISIRGE (omidubicel) by Gamida Cell (NASDAQ: GMDA), a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood.
In April 2025, CK0801, an allogeneic T regulatory (Treg) cell therapy manufactured by Cellenkos, received FDA Orphan Drug Designation for aplastic anemia, supporting its development as a novel treatment for this rare condition. A Phase III registration trial is planned for the second half of 2025, positioning CK0801 as a promising non-immunosuppressive option for aplastic anemia patients unresponsive to standard therapies.
Discover evolving trends in the Aplastic Anemia treatment landscape @ Aplastic Anemia Recent Developments.
Despite therapeutic advances, significant challenges remain in the aplastic anemia treatment landscape. Finding effective and well-tolerated treatments for patients who do not respond to standard therapies or who are unsuitable candidates for aggressive interventions continues to be problematic. Additionally, poor survival rates among older patients represent a substantial unmet medical need requiring innovative approaches.
Table of Contents
1. Key Insights
2. Executive Summary of Aplastic Anemia
3. Aplastic Anemia Competitive Intelligence
4. Aplastic Anemia: Market Overview at a Glance
5. Aplastic Anemia: Disease Background and Overview
6. Patient Journey
7. Aplastic Anemia Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Aplastic Anemia Unmet Needs
10. Key Endpoints of Aplastic Anemia Treatment
11. Aplastic Anemia Marketed Products
12. Aplastic Anemia Emerging Therapies
13. Aplastic Anemia: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Aplastic Anemia
17. KOL Views
18. Aplastic Anemia Market Drivers
19. Aplastic Anemia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Related Reports
Aplastic Anemia Pipeline Insight
Aplastic Anemia Pipeline Insight provides comprehensive insights about the Aplastic Anemia pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Aplastic Anemia companies, including Gamida-Cell, Regeneron Pharmaceuticals, and BioLineRx, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
38 minutes ago
- Globe and Mail
New Hope Vitality to Celebrate Grand Opening of Wellness Clinic in Costa Mesa
New IV Therapy & Wellness Clinic Offers Modern Treatments for Energy, Immunity, and Mental Health New Hope Vitality, formerly known as Oceans IV Hydration of Costa Mesa, is excited to announce the Grand Opening of its new wellness clinic on Saturday, June 14, 2025, from 10:00 a.m. to 3:00 p.m. The clinic is located at 1503 S Coast Dr, Suite 313, near Harbor Boulevard and the 405 freeway. New Hope Vitality provides a wide range of modern wellness treatments, including IV hydration therapy, vitamin infusions, and non-invasive mental health services. Treatments are available in-clinic, with select services offered throughout all of Orange County via mobile care. Grand Opening Celebration The Grand Opening event invites the local community to explore the clinic's offerings and enjoy exclusive perks. Guests will receive complimentary B12 or Glutathione shots, access to special discounts on wellness services, and the chance to win wellness-themed raffle prizes. The event promises a fun and energizing introduction to the New Hope Vitality experience. Modern Wellness Services New Hope Vitality offers a variety of treatments designed to support energy, recovery, and immune health. These include IV Hydration Therapy for enhanced hydration, NAD+ Therapy for cellular and cognitive function, and Vitamin Infusions and Injections for targeted nutritional support. Red Light Therapy is also available to reduce inflammation and support tissue repair. Advanced Diagnostic & Mental Wellness Care For those seeking deeper insights into their health or support for mental well-being, New Hope Vitality provides ExoMind™, an FDA-cleared TMS therapy proven effective for depression and showing promise for PTSD, OCD, ADHD, and other cognitive conditions. The clinic also offers Infrared Thermal Imaging, a non-invasive diagnostic tool used to detect early signs of inflammation and vascular concerns. For added convenience, Mobile IV Therapy services are available throughout Orange County, allowing clients to receive care in the comfort of their own homes or on-site. Event Details Location: New Hope Vitality, 1503 S Coast Dr, Suite 313, Costa Mesa, CA 92626 Date: Saturday, June 14, 2025 Time: 10:00 a.m. – 3:00 p.m. Phone: (223) 223-9355 RSVP: About New Hope Vitality New Hope Vitality, formerly known as Oceans IV Hydration of Costa Mesa, is a modern IV therapy and wellness clinic now reopening under a new name and expanded vision. The clinic offers a comprehensive range of integrative wellness services, including IV hydration, NAD+ therapy, vitamin infusions and injections, red light therapy, infrared thermal imaging, and FDA-cleared ExoMind™ TMS therapy. With its Grand Opening event on June 14, 2025, New Hope Vitality invites the community to experience personalized, science-backed care designed to support energy, immunity, recovery, and long-term wellness—inside and out. Facebook: Instagram: Media Contact Company Name: NewHope Vitality Contact Person: Freddie Schmidt Email: Send Email Phone: 223-223-9355 Address: 1503 S Coast Dr Suite 313 City: Costa Mesa State: CA Country: United States Website:
CTV News
an hour ago
- CTV News
Restless legs syndrome: A common sleep disorder you may never have heard of
Behavioural changes and medication could help if you have restless legs syndrome, experts say. AndreyPopov/iStockphoto/Getty Images/File via CNN Newsource Karla Dzienkowski's daughter was 11 when she started coming into her mom's room at night saying she couldn't fall asleep because of a stabbing feeling in her legs. She had to walk to make it stop. The preteen became cranky and tired. Her grades started to slip, and she even fell asleep on a bench during a family trip to an amusement park, Dzienkowski said. It took three years, but Dzienkowski's family finally got an explanation for the girl's condition: restless legs syndrome. One study estimates 4% to 29% of adults in Western industrialized countries have restless legs syndrome. It is a condition that too few people can recognize in themselves, and many doctors don't know how to manage properly, said Dzienkowski, a nurse who is executive director of the Restless Legs Syndrome Foundation. Here is what experts want you to know about restless legs syndrome. What is restless legs syndrome? 'Restless legs syndrome is a neurological disorder that is characterized by a need to move that is oftentimes associated with an uncomfortable feeling,' said Dr. John Winkelman, chief of the sleep disorders clinical research program at Massachusetts General Hospital and professor of psychiatry at Harvard Medical School. The uncomfortable feeling — described as crawling, aching, tingling or throbbing — is often in the legs and sometimes the arms, he added. Restlessness frequently happens when people with the condition are sitting or lying down, and it is relieved with movement, Winkelman said. Symptoms are more likely to occur when a person is at rest, most often at night, and because the syndrome interferes with sleep, it is classified as a sleep disorder, Winkelman said. In moderate to severe cases, people experience restless legs syndrome several times a week, and in the most extreme cases, symptoms can delay sleep for several hours, said Dr. Brian Koo, associate professor of neurology at Yale School of Medicine and director of the Yale Center for Restless Legs Syndrome. Who gets it? Two strong components play a role in who gets restless legs syndrome: genetics and iron levels. Restless legs syndrome often runs in families, and genetic markers make up about 20% of the prediction of who will get it, Winkelman said. Those with an iron deficiency are also more likely to get restless legs syndrome, including people who are pregnant, on dialysis, who are menstruating, who have anemia, or who are vegetarians, Winkelman said. Those on selective serotonin reuptake inhibitor antidepressants may also be vulnerable to restless legs syndrome, he added. The condition is twice as common in women as in men and much more common as people get older, Winkelman said. However, as Dzienkowski learned, children can have restless legs syndrome, too. Treatment with lifestyle changes To treat restless legs syndrome, a good first step is to look at what might be making the condition worse, Winkelman said. Alcohol, other medications and simple sugars may contribute to symptoms, Koo said. If iron is low — or even borderline low — oral iron supplements or intravenous iron infusions may help, Winkelman added. Dzienkowski also recommends having a 'bag of tricks' to manage symptoms, such as hot or cold packs, massages, walks or some mind-stimulating activity. 'For some reason … if you keep your mind engaged, it helps to keep symptoms at bay,' she said. Medications that can help There are medications that help if lifestyle changes and iron supplementation don't work. Many doctors will start with a class of drugs called alpha2-delta ligands, such as gabapentin or pregabalin, Koo said. For a long time, dopamine agonists were the first line of medications. But they are now prescribed infrequently because they can worsen restless legs syndrome over time, Winkelman added. The medications for the most severe cases are low-dose, long-acting opioid medications, Koo said. Talk to a doctor If you have discomfort that motivates you to move your legs at rest — particularly if doing so disturbs your sleep — talk to a doctor, Dzienkowski said. Not all medical professionals are well versed in restless legs syndrome, so asking for a referral to a sleep specialist may be helpful, she said. You should also get your lab work done, especially an iron panel with ferritin, a blood test that looks at how much iron your body has and how available it is for use, Dzienkowski said. 'The sooner you do it, the better, because you're just delaying diagnosis and treatment, which can be detrimental to your life,' she said. 'You don't realize that that sleepiness that you're feeling at work or the crankiness or you're not wanting to get out and do things could be the RLS bleeding into your daytime. … At least go have that conversation.'
Globe and Mail
3 hours ago
- Globe and Mail
Poultry Medicine/Pharmaceuticals Market to Hit USD 6.68 Billion by 2029 with 5.9% CAGR
"The key players in the global poultry medicine/pharmaceuticals market are MSD (US), Elanco (US), Boehringer Ingelheim (Germany), Ceva Sante Animale (France), Zoetis Service LLC (US), Virbac (France), Phibro Animal Health (US), Hester Biosciences Limited (India)" Browse 500 market data Tables and 56 Figures spread through 424 Pages and in-depth TOC on "Poultry Medicine/Pharmaceuticals Market by Animal Type (Chickens, Turkeys, Ducks), Product (Drugs, Vaccines, Feed Additives), Disease Indication (Newcastle disease, Infectious Bursal Disease, Salmonella), Route of Administration - Global Forecast to 2029 The poultry medicine/pharmaceuticals market valued at US$ 4.73 billion in 2023, is forecasted to grow at a robust CAGR of 5.9%, reaching US$ 5.01 billion in 2024 and an impressive US$ 6.68 billion by 2029. The growth of the poultry medicine/pharmaceutical industry can be attributed to the rising global population and consumption of poultry meat and eggs leading to more poultry farming practiced notably in the developing regions where poultry is the cheapest source of protein. This growth in poultry medicine/production also brings with it the challenge of disease prevention and control as poultry is often attacked by diseases like Newcastle disease and coccidiosis. Enhanced consumer consciousness, safety concerns and strict law compliance towards the use of antibiotics in food animals have also influenced the market demand in that there is a high demand of vaccines, probiotics, and immune boosters as opposed to antibiotics. In addition to advancements in means of disease control growth enhancing products such as vaccines, in ovo vaccination technology geared towards delivery of vaccines has also worked to enhanced control of diseases among large scale farms. As such, with the emerging regions in Asia, Latin America and Africa increasing poultry production at an exponential rate, the market has also been enhancing towards supplying health solutions for healthy and productive farming dominantly in the sustainable manner. Browse in-depth TOC on " Poultry Medicine/Pharmaceuticals Market" 500 - Tables 56 - Figures 424 - Pages Based on animal type, the chickens registered the highest share in cold plasma market, people all over the world eat a lot of chicken and eggs, which makes them affordable sources of protein. For this reason, poultry farming has recorded a high level of growth especially in developing economies that have dense populations and elevated rates of urbanization which call for higher levels of production. Moreover, chickens are quite susceptible to other infectious agents such as Newcastle disease, Infectious Bronchitis, and Coccidiosis, which calls for adequate vaccinations and attention to drugs in order to sustain the health and the productiveness of the flock maintained. Also, as poultry farming has a high risk of diseases that have a dramatically negative effect on the economy and the poultry markets, there has been an increase in the measures put on the production of chicken meat and eggs among others. Thus a lot of research and development is being directed by the pharmaceutical companies into the development of products for the chickens which is the leading segment of the poultry medicine/pharmaceuticals market. Based on product, vaccines hold the most significant market share of the poultry medicine/pharmaceuticals, due to their necessity for controlling diseases, which are integral to large-scale poultry farming. These birds, especially chickens, are prone to highly contagious diseases like Newcastle disease, Infectious Bronchitis, and Avian Influenza. When not controlled, they have the potential to incur the greatest losses. Vaccination is an effective tool that controls these diseases and therefore improves the health of a flock and enhances productivity. In addition, the greater regulatory pressure to reduce the use of antibiotics in livestock production makes poultry producers increasingly rely on vaccines as a means of disease prevention that is not reliant on antibiotics, thus assisting in the fight against problems of antibiotic resistance. Ongoing innovations in vaccine technology, such as in ovo (in-egg) vaccination, make it possible to achieve efficient mass immunization, saving time and labor while improving disease control on large farms. The vaccines are now the most preferred choice in ensuring sustainable control of poultry diseases, hence placing them in the limelight in the poultry medicine/pharmaceuticals market, with a resultant increasing demand for safer poultry products. Based on disease indication, newcastle disease hold the most significant market share of the poultry medicine/pharmaceuticals, due to its severe economic and production impacts on the global poultry industry. As a highly infectious viral disease, it poses a major threat to flock health, leading to high mortality rates, reduced productivity, and trade restrictions in outbreak scenarios. The live attenuated, inactivated, and recombinant vaccines have dominated this market segment widely. Moreover, increased awareness, government-ordered vaccination programs, and continuous improvement in vaccine technology, such as thermostable and vector-based solutions, continue to strengthen newcastle disease as the prime concern in poultry disease control strategies. Based on route of administration, the oral route of administration is the most practical, efficient, and economic route for treatment delivery in large flocks. The major reason why poultry producers prefer oral administration is that it is relatively easy to administer the medicine through water or feed; it will ensure all birds receive the necessary dose without the need for individual handling, which would be both labor-intensive and stressful to the birds. This route is especially advantageous in preventive care, wherein drugs such as antibiotics, probiotics, and vitamins can be added to water systems and arrive quickly at the birds' consumption sites, reducing diseases from spreading among flocks. The oral method can also be delivered flexibly, and its use is better for vaccines, probiotics, and immune boosters that play a vital role in maintaining health and productivity in the flocks. Oral administration is easy and scalable, which places it as the first option for large-scale poultry operations. This cements its foremost position in the poultry medicine/pharmaceuticals market. Based on region poultry medicine/pharmaceuticals market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Asia-Pacific region has the highest market share of poultry medicine/pharmaceuticals as the poultry industry is experiencing high growth rates, mostly on account of the soaring demand for readily affordable sources of protein like chicken and eggs. Such a demand is also seen across China, India, and Indonesia, primarily supported by the population growth, middle-class expansion, and urbanization of the populace that consumes meat in larger quantities. This demand has been fueled by the increasing number of large-scale poultry farms in the region and the susceptibility of the region to infectious poultry diseases, including Avian Influenza, Newcastle disease, and Infectious Bronchitis. The prominent players in the poultry medicine/pharmaceuticals market are MSD (US), Elanco (US), Boehringer Ingelheim (Germany), Ceva Sante Animale (France), Zoetis Service LLC (US), Virbac (France), Phibro Animal Health (US). MSD (US) MSD Animal Health is one of the top companies in the global animal health sector and an important player in the market of poultry pharmaceuticals. With extensive range of products devoted to poultry health, MSD has made inroads in developed markets with vaccines, novel drug delivery systems, and sophisticated disease prevention and treatment modalities. The company's main objective is improving productivity and animal health, more specifically for the poultry industry the problems of infectious agents, respiratory problems, and growth promotion. ELANCO (US) Elanco Animal Health, a global leader in animal health, has established a significant market share in poultry medicine/pharmaceuticals. Elanco's approach to poultry medicine/pharmaceuticals has allowed it to create a variety of necessary solutions to the critical health needs in poultry farming ranging from infectious diseases to parasite management. The product portfolio of the world leader, it includes antibiotics, vaccines, anticoccidials, parasiticides, nutritional health and other solutions. The product is well accepted in the markets globally and especially in the Americas, Europe and Asia pacific regions. R&D becomes one of the major driver of such growth and new strategies within the company focus on partnering with universities and other biotech companies to enhance the company's pipeline of products. BOEHRINGER INGELHEIM (GERMANY) Boehringer Ingelheim, located in Germany, is one of the major players globally in animal medicines, specifically in the poultry division engaged in the enhancement of poultry health with the help of vaccines, therapeutics, and biosecurity measures. Boehringer Ingelheim's unyielding focus on R&D is to enhance the Company's product pipeline especially towards vaccine development and non-antibiotic treatments. In addition, the company has a solid presence across the globe enabling it to operate in different regulatory regimes without any challenges. All these strengths in addition to sustainability and provision of extension services to the farmers enable Boehringer Ingelheim to dominate the global poultry medicine/pharmaceutical market, which has current and future promises of healthy and sustainable poultry production. For more information, Inquire Now!
